Objectives: More than 10% of the world’s population is affected by infertility which might have social, psychological and economic consequences both for the individual and society. Our aim was to determine the annual health insurance treatment cost of female infertility associated with anovulation in Hungary.

Methods: Data were derived from the financial database of the National Health Insurance Fund Administration (NHIFA), for the year 2019. Data analysed included annual health insurance costs, patient numbers and cost distribution calculated for age groups. The following cost categories were included into the study: general practice care, home care, in- and outpatient care, medical imaging, laboratory diagnostics, pharmaceuticals and medical aids. Patients with female infertility associated with anovulation were identified with the following code of the International Classification of Diseases 10^th revision: N97.0.

Results: In 2019, the NHIFA spent 100.86 million Hungarian Forints (HUF) on the treatment of patients with female infertility associated with anovulation which equals to 347.00 thousand American Dollars (USD), or 309.99 thousand Euros (EUR). The highest patient numbers were in use of pharmaceuticals (1,952 women) and outpatient care (1,952 women). Pharmaceuticals (60.8% of total health insurance costs), acute inpatient care (27.3%) and outpatient care (6.7%) were the main cost drivers, while all other forms of medical care amounted to 5.2%. The annual health care treatment cost per patient was 51,668 HUF (178 USD/159 EUR).

Conclusions: Use of pharmaceuticals was the major cost driver in the treatment of female infertility associated with anovulation. Distribution of the annual health care treatment cost per patient of use of pharmaceuticals showed a significant difference among age groups. It was the highest in the ‘40-49’ age group.